PT - JOURNAL ARTICLE ED - , TI - Ocrelizumab for multiple sclerosis AID - 10.1136/dtb.2018.7.0646 DP - 2018 Jul 01 TA - Drug and Therapeutics Bulletin PG - 80--84 VI - 56 IP - 7 4099 - http://dtb.bmj.com/content/56/7/80.short 4100 - http://dtb.bmj.com/content/56/7/80.full SO - Drug Ther Bull2018 Jul 01; 56 AB - â–¼Ocrelizumab (Ocrevus - Roche Registration GmbH) has received marketing authorisation approval from the European Medicines Agency (EMA) for the treatment of adults with multiple sclerosis.1,2 It is the first drug to be licensed for use in early primary progressive multiple sclerosis and relapsing forms of multiple sclerosis. Here, we review the evidence for the safety and effectiveness of ocrelizumab.